Welcome to our dedicated page for Marex Group plc SEC filings (Ticker: MRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Commodity spreads, derivative exposures and multi-jurisdiction capital rules make Marex Group plc鈥檚 disclosures dense reading. If you鈥檝e ever searched 鈥渨here to find Marex Group quarterly earnings report 10-Q filing鈥� or wondered about 鈥淢arex Group insider trading Form 4 transactions,鈥� you know the challenge. Each 10-K spans hundreds of pages detailing liquidity provision, clearing risk and segment performance across energy, metals and agricultural markets鈥攄ata traders, hedge funds and corporate treasurers can鈥檛 ignore.
Stock Titan turns that complexity into clarity. Our AI-powered summaries translate VaR tables, regulatory-capital notes and hedging footnotes into plain language so you can understand Marex Group SEC documents with AI in minutes, not hours. AG真人官方-time alerts surface Marex Group Form 4 insider transactions, while instant tagging links every Marex Group 8-K material events explained to its exact page reference. You鈥檒l also find the Marex Group proxy statement executive compensation details and the Marex Group annual report 10-K simplified for quick comparison.
Whether you need Marex Group earnings report filing analysis to gauge trading-revenue trends or want to track Marex Group executive stock transactions Form 4 before commodity price swings, every document appears here the moment EDGAR updates. Drill into segment notes directly from your dashboard, export cash-flow tables, or set custom watchlists for new 10-Q or 8-K releases. Investors, analysts and risk officers finally have a single view of Marex Group SEC filings explained simply鈥攑owered by AI and ready whenever markets move.
BioSig Technologies (BSGM) has called a virtual special meeting to seek shareholder approval for several highly dilutive and governance-altering actions tied to its recently closed acquisition of Streamex Exchange Corp.
- Proposal 1: Ratify issuance of 鈮�109.1 million common shares (plus one Super Voting Preferred share) to Streamex sellers. If approved, Streamex holders would ultimately control 75% of BioSig鈥檚 fully-diluted equity; existing investors fall to 25%.
- Proposal 2: Authorize stock underlying convertible debentures to YA II PN, Ltd.
- Proposal 3: Add 10,359,211 shares to the 2023 LTIP (total 14,735,806).
- Proposal 4: Permit issuance of 鈮�19.99% of outstanding shares under a Standby Equity Purchase Agreement (SEPA) with Yorkville.
- Proposal 5: Increase authorized common shares from 200 million to 500 million.
- Proposal 6: Stagger the board into three classes.
The board unanimously recommends voting 鈥淔OR鈥� all proposals. Quorum is one-third of voting power; most items need simple majority of votes cast, but the classified board requires majority of all outstanding shares. Risk disclosure highlights extensive dilution, regulatory uncertainty around Streamex鈥檚 gold-tokenization model, and integration challenges. Record date and meeting date remain blank pending SEC clearance.
BioSig Technologies (BSGM) has called a virtual special meeting to seek shareholder approval for several highly dilutive and governance-altering actions tied to its recently closed acquisition of Streamex Exchange Corp.
- Proposal 1: Ratify issuance of 鈮�109.1 million common shares (plus one Super Voting Preferred share) to Streamex sellers. If approved, Streamex holders would ultimately control 75% of BioSig鈥檚 fully-diluted equity; existing investors fall to 25%.
- Proposal 2: Authorize stock underlying convertible debentures to YA II PN, Ltd.
- Proposal 3: Add 10,359,211 shares to the 2023 LTIP (total 14,735,806).
- Proposal 4: Permit issuance of 鈮�19.99% of outstanding shares under a Standby Equity Purchase Agreement (SEPA) with Yorkville.
- Proposal 5: Increase authorized common shares from 200 million to 500 million.
- Proposal 6: Stagger the board into three classes.
The board unanimously recommends voting 鈥淔OR鈥� all proposals. Quorum is one-third of voting power; most items need simple majority of votes cast, but the classified board requires majority of all outstanding shares. Risk disclosure highlights extensive dilution, regulatory uncertainty around Streamex鈥檚 gold-tokenization model, and integration challenges. Record date and meeting date remain blank pending SEC clearance.
Marex Group has filed a Form 144 notice for the proposed sale of 210,000 shares of common stock through J.P. Morgan Securities, with an aggregate market value of $8,219,400. The sale is scheduled for June 23, 2025, on the Nasdaq exchange.
The securities to be sold were acquired through multiple compensation grants:
- May 2024: 29,243 shares total
- March 2025: 105,122 shares total
- May 2025: 75,635 shares
The total shares outstanding are 71,231,706. The proposed sale represents approximately 0.29% of outstanding shares. No securities were reported sold by the filer during the past three months. This Form 144 filing indicates insider's intention to sell while affirming no knowledge of undisclosed material adverse information about the company.
FAQ
What is the current stock price of Marex Group plc (MRX)?
What is the market cap of Marex Group plc (MRX)?
What is the core business of Marex Group plc?
Which key segments does Marex operate in?
How does Marex enhance market liquidity?
Who are the primary clients of Marex Group plc?
What differentiates Marex from its competitors?
What types of markets does Marex serve?
How does Marex manage regulatory and technological complexities?
